Multifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in alzheimer’s disease mouse models

Journal of Neuroscience

Volumn 34, Issue 42, 2014, Pages 14022-14031

  Balducci, Claudia ^a   Mancini, Simona ^b   Minniti, Stefania ^b   La Vitola, Pietro ^a   Zotti, Margherita ^a   Sancini, Giulio ^b   Mauri, Mario ^b   Cagnotto, Alfredo ^a   Colombo, Laura ^a   Fiordaliso, Fabio ^a   Grigoli, Emanuele ^a   Salmona, Mario ^a   Snellman, Anniina ^c   Haaparanta Solin, Merja ^c   Forloni, Gianluigi ^a   Masserini, Massimo ^b   Re, Francesca ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Abeta; Alzheimer; Cognitive impairment; Liposomes; Nanomedicine; Oligomers

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; LIPOSOME; PHOSPHATIDIC ACID; PITTSBURGH COMPOUND B; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; POSITRON EMISSION TOMOGRAPHY; RECEPTOR BINDING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; DISEASE MODEL; MEMORY DISORDERS; METABOLISM; PATHOLOGY; PLAQUE, AMYLOID; RANDOMIZATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS E; DISEASE MODELS, ANIMAL; LIPOSOMES; MALE; MEMORY DISORDERS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; RANDOM ALLOCATION;

EID: 84907983707     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0284-14.2014     Document Type: Article

References (37)

1. Agostinho P, Cunha RA, Oliveira C (2010) Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease. Curr Pharm Des 16: 2766–2778.
2. Ahyayauch H, Raab M, Busto JV, Andraka N, Arrondo JL, Masserini M, Tvaroska I, Gon˜i FM (2012) Binding of /3-amyloid (1–42) peptide to negatively charged phospholipid membranes in the liquid-ordered state: modeling and experimental studies. Biophys J 103:453–463.
3. Antunes M, Biala G (2012) The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process 13:93-110.
4. Balducci C, Forloni G (2011) APP transgenic mice: their use and limitations. Neuromolecular Med 13:117–137.
5. Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, Chiesa R, Gobbi M, Salmona M, Forloni G (2010) Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci USA 107:2295–2300.
6. Bana L, Minniti S, Salvati E, Sesana S, Zambelli V, Cagnotto A, Orlando A, Cazzaniga E, Zwart R, Scheper W, Masserini M, Re F (2013) LIPosomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect A/3 aggregation features and cross the blood-brain-barrier: implications for therapy of Alzheimer Disease. Nanomedicine. Advance online publication. Retrieved September 9, 2014. doi:10.1016/j.nano.2013.12.001.
7. Bertram L, Tanzi RE (2012) The genetics of Alzheimer’s disease. Prog Mol Biol Transl Sci 107:79–100.
8. Biscaro B, Lindvall O, Hock C, Ekdahl CT, Nitsch RM (2009) Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice. J Neurosci 29:14108–14119.
9. Brambilla D, Le Droumaguet B, Nicolas J, Hashemi SH, Wu LP, Moghimi SM, Couvreur P, Andrieux K (2011) Nanotechnologies for Alzheimer’s disease: diagnosis, therapy, and safety issues. Nanomedicine 7:521–540.
10. Bruggink KA, Müller M, Kuiperij HB, Verbeek MM (2012) Methods for analysis of amyloid-beta aggregates. J Alzheimers Dis 28:735–758.
11. Chang HI, Yeh MK (2012) Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 7:49–60.
12. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8:79–84.
13. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335:1503–1506.
14. Datta G, Chaddha M, Garber DW, Chung BH, Tytler EM, Dashti N, Bradley WA, Gianturco SH, Anantharamaiah GM (2000) The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry 39:213–220.
15. Gobbi M, Re F, Canovi M, Beeg M, Gregori M, Sesana S, Sonnino S, Brogioli D, Musicanti C, Gasco P, Salmona M, Masserini ME (2010) Lipid-based nanoparticles with high binding affinity for amyloid-beta1–42 peptide. Biomaterials 31:6519–6529.
16. Ito S, Matsumiya K, Ohtsuki S, Kamiie J, Terasaki T (2013) Contributions of degradation and brain-to-blood elimination across the blood-brain barrier to cerebral clearance of human amyloid-beta peptide(1–40) in mouse brain. J Cereb Blood Flow Metab 33:1770–1777.
17. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17:157–165.
18. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120:701–713.
19. Lee MK, Borchelt DR, Kim G, Thinakaran G, Slunt HH, Ratovitski T, Martin LJ, Kittur A, Gandy S, Levey AI, Jenkins N, Copeland N, Price DL, Sisodia SS (1997) Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat Med 3:756–760.
20. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 155:853–862.
21. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K (2003) Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 23:29–33.
22. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46: 860–866.
23. Palop JJ, Mucke L (2010) Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci 13:812–818.
24. Re F, Cambianica I, Sesana S, Salvati E, Cagnotto A, Salmona M, Couraud PO, Moghimi SM, Masserini M, Sancini G (2010) Functionalization with ApoE-derived peptides enhances the interaction with brain capillary en-dothelial cells of nanoliposomes binding amyloid-beta peptide.J Biotech-nol 156:341–346.
25. Re F, Cambianica I, Zona C, Sesana S, Gregori M, Rigolio R, La Ferla B, Nicotra F, Forloni G, Cagnotto A, Salmona M, Masserini M, Sancini G (2011) Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across ablood-brain barrier model. Nanomedicine 7:551–559.
26. Re F, Gregori M, Masserini M (2012) Nanotechnology for neurodegenera-tive disorders. Maturitas 73:45–51.
27. Scopes DI, O’Hare E, Jeggo R, Whyment AD, Spanswick D, Kim EM, Gannon J, Amijee H, Treherne JM (2012) Abeta oligomer toxicity inhibitor protects memory in models of synaptic toxicity. BrJ Pharmacol 167:383–392.
28. Selkoe D, Mandelkow E, Holtzman D (2012) Deciphering Alzheimer disease. Cold Spring Harb Perspect Med 2:11460.
29. Snellman A, López-Picón FR, Rokka J, Salmona M, Forloni G, Scheinin M, Solin O, Rinne JO, Haaparanta-Solin M (2013) Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of alzheimer disease. J Nucl Med 54:1434–1441.
30. Steinerman JR, Irizarry M, Scarmeas N, Raju S, Brandt J, Albert M, Blacker D, Hyman B, Stern Y (2008) Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch Neurol 65:906– 912.
31. Sutcliffe JG, Hedlund PB, Thomas EA, Bloom FE, Hilbush BS (2011) Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer’s disease. J Neurosci Res 89:808–814.
32. Tanifum EA, Dasgupta I, Srivastava M, Bhavane RC, Sun L, Berridge J, Pour-garzham H, Kamath R, Espinosa G, Cook SC, Eriksen JL, Annapragada A (2012) Intravenous delivery of targeted liposomes to amyloid/3 pathology in APP/PSEN1 transgenic mice. PLoS One 7:48515.
33. Valero J, Espanã J, Parra-Damas A, Martín E, Rodríguez-Alvarez J, Saura CA (2011) Short-term environmental enrichment rescues adult neurogenesis and memory deficits in APP(Sw, Ind) transgenic mice. PLoS One 6:16832.
34. Verbeek MM, Ruiter DJ, De Waal RM (1997) The role of amyloid in the pathogenesis of Alzheimer’s disease. Biol Chem 378:937–950.
35. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535–539.
36. Wan L, Pooyan S, Hu P, Leibowitz MJ, Stein S, Sinko PJ (2007) Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarri-ers for improving HIV drug delivery. Pharm Res 24:2110–2119.
37. Wilcox KC, Lacor PN, Pitt J, Klein WL (2011) Abeta oligomer-induced synapse degeneration in Alzheimer’s disease. Cell Mol Neurobiol 31:939-948.